Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Language
Publication year range
1.
Nucl Med Mol Imaging ; 53(1): 71, 2019 02.
Article in English | MEDLINE | ID: mdl-30828404

ABSTRACT

[This corrects the article DOI: 10.1007/s13139-016-0395-z.].

2.
Article in English | WPRIM (Western Pacific) | ID: wpr-750643

ABSTRACT

@#Introduction: There are two dosing methods for radioiodine dose administration including empirical fixed dose and calculated dose. Recent meta-analysis supported that dose calculation is better than empirical fixed dose. However, dose calculation by dosimetry or 24 hours radioiodine uptake ratio can be tedious. Pertechnetate thyroid scintigraphy is a simple nuclear imaging that can be completed on the same day and pertechnetate thyroid uptake ratio determined from the scintigraphy can be used to calculate the radioiodine dose. This research is done to measure the efficacy of the calculated dose regime. Methods: Hyperthyroidism patients referred for first radioiodine therapy were recruited. Pertechnetate thyroid scintigraphy was done and pertechnetate uptake ratio used for dose calculation. The outcome of the treatment was determined at six months. Results: A total of 95 patients were recruited. Six months after treatment, 82.1% of the calculated dose cohort achieved euthyroid or hypothyroid state. Participants with multinodular goitre had higher failure rate than those with Graves’ disease (p=0.032) although there was no difference in the median RAI dose given (p=0.866). Conclusion: This calculated dose method showed good outcome with 82.1% cure rate at six months post treatment.


Subject(s)
Hyperthyroidism
3.
Nucl Med Mol Imaging ; 51(2): 195-196, 2017 06.
Article in English | MEDLINE | ID: mdl-28559948

ABSTRACT

Tenofovir, used in the treatment of chronic hepatitis B and HIV, is known for its side effects on the kidneys and bones. We share interesting images of a patient with tenofovir-induced osteomalacia on Technetium-99 m hydroxymethyelene (Tc-99 m HDP) bone scintigraphy. Pattern recognition of this bone scintigraphy and correlation with the clinical history is essential to avoid misdiagnosis.

4.
Article in English | WPRIM (Western Pacific) | ID: wpr-786911

ABSTRACT

Tenofovir, used in the treatment of chronic hepatitis B and HIV, is known for its side effects on the kidneys and bones. We share interesting images of a patient with tenofovir-induced osteomalacia on Technetium-99 m hydroxymethyelene (Tc-99 m HDP) bone scintigraphy. Pattern recognition of this bone scintigraphy and correlation with the clinical history is essential to avoid misdiagnosis.


Subject(s)
Humans , Diagnostic Errors , Hepatitis B , Hepatitis B, Chronic , Hepatitis, Chronic , HIV , Kidney , Osteomalacia , Radionuclide Imaging , Tenofovir
SELECTION OF CITATIONS
SEARCH DETAIL
...